Neogen Corporation ( NEOG Quick Quote NEOG - Free Report) reached a new 52-week high of $92.98 on Apr 9 before closing the session marginally lower at $92.55. The stock has rallied 8.3% since its third-quarter fiscal 2021 earnings announcement on Mar 23.
The company is witnessing an uptrend in its stock price, prompted by a robust performance in both its Animal Safety and Food Safety segments during the fiscal third quarter, which in turn, is enabling it to gain a strong market share. Recent product launches hold strong prospects for the company’s growth, which raise optimism on the stock. However, tough competition is a cause for concern.
Key Growth Catalysts Impressive Q3 Performance: During the fiscal third quarter, the company’s Animal Safety revenues were $58.3 million, up 18.1% year over year. This upside can be attributed to a 79% increase in sales of rodenticides within its product line including significantly higher sales in the U.S. Pacific Northwest of products. It registered Food Safety revenues of $58.4 million, reflecting 15.7% (up 11% organically) year-over-year growth.The acquisitions of international distributors in the second half of fiscal 2020 and Megazyme, a food quality diagnostics company, contributed to growth.
Neogen’s International business grew 16% in the reported quarter, partly owing to two months of sales from the Megazyme buyout. Revenues from Neogen’s worldwide animal genomics business rose 10% year over year, primarily led by a 19% improvement in sales in the global swine industry.
Collaborations: In March 2021, the company acquired the assets of Chile-based Magiar Chilena(Magiar), a distributor of food, animal and plant diagnostics comprising Neogen products. Neogen will integrate the Magiar assets into its wholly-owned subsidiary Neogen Chile SpA for continued operations in the country. Further, in January, the company purchased Ireland-based Megazyme, Ltd., a major supplier of analytical solutions utilized by quality control laboratories in the global food and beverage space. The takeover of Megazyme provides Neogen with a natural and complementary expansion of its food diagnostics portfolio while at the same time aligning with an aim to offer a comprehensive site of leading solutions to global food producers.
Last November, the company entered into a partnership with Transnetyx, Inc. to collaborate on distribution and advancement of the miniMUGA genotyping array (Mouse Universal Genotyping Array). Notably, Neogen intends to leverage Transnetyx’s wide-reaching footprint in the model organism community via this collaboration.
Product Launches: In February 2021, the company announced the unveiling of its Early Warning COVID-19 Testing for wastewater. Notably, this piloted, accurate and reliable test is expected to monitor the presence of the COVID-19 virus SARS-CoV-2 in sludge from wastewater facilities. Earlier in January, the company announced the launch of Reveal Q+ for the Aflatoxin M1 test, a faster and easier test to detect the presence of cancer-causing toxin aflatoxin M1. Last December, the company introduced the Igenity Canine Wellness, a preventative care DNA screening tool for veterinarians. Downsides Coronavirus Concern: Over the past few months, the coronavirus pandemic has wreaked havoc on the company’s stock. Neogen continues to be adversely impacted by the pandemic-led global market disruptions, especially in the food industry across some of its important end markets in the United States and Europe due to the lockdowns and social-distancing restrictions still in place. Neogen’s disinfectant sales declined 9% in third-quarter 2021, resulting from lower sales of water treatment products due to COVID restrictions. Price Performance
In the past year, the stock has gained 48.6% compared with 23.4% growth of the
industry. Zacks Rank and Key Picks
Currently, Neogen has a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are
HillRom Holdings ( HRC Quick Quote HRC - Free Report) , Surmodics ( SRDX Quick Quote SRDX - Free Report) and Veeva Systems ( VEEV Quick Quote VEEV - Free Report) . While Surmodics currently sports a Zacks Rank #1 (Strong Buy), the other two presently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
HillRom has a projected long-term earnings growth rate of 7.3%.
Surmodics has a projected long-term earnings growth rate of 10%.
Veeva has an estimated long-term earnings growth rate of 14.5%.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>